A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma

Metastatic Melanoma Clinical Trial

Official title:

A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma (ILLUMINATE-204)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02644967
• Other study ID #: 2125-204
• Secondary ID: ILLUMINATE-204
• Status: Completed
• Phase: Phase 2
• Start date: December 2015
• Est. completion date: May 2021

Study information

• Verified date: July 2022
• Source: Idera Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of the Phase 1 study was to find the recommended Phase 2 dose of the study drug IMO-2125 (tilsotolimod) that can be given in combination with ipilimumab (ipi) or pembrolizumab (pembro) to participants with metastatic melanoma and assess the safety, tolerability, pharmacokinetics (PK), and immunogenicity when administered in combination with ipilimumab or pembrolizumab.

Description:

The open-label single-arm Phase 2 study was designed to assess the recommended dose for safety, tolerability, pharmacokinetics (PK), immunogenicity, and efficacy of 8 mg IMO-2125 (tilsotolimod) when administered in combination with ipilimumab.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: May 2021
• Est. primary completion date: February 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have histologically confirmed metastatic melanoma with measurable, stage III (lymph node or in transit lesions) or stage IVA, IVB, or IVC disease.

2. Patients must have symptomatic or radiographic progression during or after treatment with a PD-(L)1 inhibitor administered either as monotherapy or in combination.

1. The interval between last PD-(L)1 directed treatment and start of study treatment should be at least 21 days.

2. Prior BRAF or MEK inhibitor treatment is not required. However, for patients with known BRAF status:

• Those with BRAF wild type may have had a maximum of two previous systemic regimens for the treatment of melanoma.

• Those with a BRAF mutation may have had a maximum of three previous systemic regimens for the treatment of melanoma.

3. Prior ipilimumab is permitted.

4. Previous treatment with either a PD-1 inhibitor (for patients enrolling on the IMO-2125 + pembrolizumab combination) or CTLA-4 inhibitor (for patients enrolling on the IMO-2125 + ipilimumab combination if applicable) should not have been accompanied by DLT for which permanent discontinuation is recommended (per USPI).

• Patients with a history of Grade =2 gastrointestinal symptoms (e.g., diarrhea, colitis) during prior checkpoint inhibitor treatment should be discussed with the Idera Medical Monitor during the Screening Period before starting study treatment.

3. Phase 1 patients must have at least two measurable tumor lesions = 1.0 cm that are accessible to biopsy. Phase 2 patients must have at least one measurable lesion (per RECIST v1.1) which may be the same site that is used for the intratumoral injections.

4. Patients must be = 18 years of age.

5. Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status = 2.

6. Patients must meet the following laboratory criteria:

1. Absolute neutrophil count (ANC) = 1.5 x 10^9/L (1500/mm3)

2. Platelet count = 75 x 10^9/L (75,000/mm3)

3. Hemoglobin = 8.0 g/dL (4.96 mmol/L)

4. Serum creatinine = 1.5 x upper limit of normal (ULN) or calculated creatinine clearance = 60 mL/minute

5. Aspartate aminotransferase (AST) = 2.5 x ULN; alanine aminotransferase (ALT) = 2.5 x ULN; AST/ALT < 5 x ULN if liver involvement

6. Serum bilirubin = 1.5 x ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin < 3 mg/dL

7. Women of childbearing potential (WOCBP) and men must agree to use effective contraceptive methods from Screening throughout the study treatment period and until at least 90 days after the last dose of IMO-2125, 3 months after the last dose of ipilimumab or at least 4 months after the last dose of pembrolizumab.

8. Patients must have an anticipated life expectancy > 3 months.

Exclusion Criteria:

1. Patients who have received prior therapy with a TLR agonist, excluding topical agents. Patients who have received experimental vaccines or other investigational immune therapies should be discussed with the Medical Monitor to confirm eligibility.

2. Patients who have received systemic treatment with IFN-a within the previous 6 months prior to enrolling into this study.

3. Patients with known hypersensitivity to any oligodeoxynucleotide.

4. Patients with active autoimmune disease requiring disease-modifying therapy.

5. Patients requiring concurrent systemic steroid therapy higher than physiologic dose (7.5 mg/day of prednisone).

6. Patients with any form of active primary or secondary immunodeficiency.

7. Patients with another primary malignancy that has not been in remission for at least 3 years.

8. Patients with active systemic infections requiring antibiotics or active hepatitis A, B, or C.

9. Patients with a known diagnosis of human immunodeficiency virus (HIV) infection.

10. Patients who previously had a severe reaction to treatment with a human antibody.

11. Patients with known central nervous system, meningeal, or epidural disease.

12. Women who are pregnant or breastfeeding.

13. Patients with impaired cardiac function or clinically significant cardiac disease.

14. Patients with ocular melanoma.

Related Conditions & MeSH terms

• Melanoma
• Metastatic Melanoma

Intervention

Drug:
• IMO-2125
Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
• Ipilimumab
4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	Gabrail Cancer Center	Canton	Ohio
United States	MD Anderson Cancer Center	Houston	Texas
United States	University of Iowa Hospitals and Clinics	Iowa City	Iowa
United States	Vanderbilt-Ingram Cancer Center	Nashville	Tennessee
United States	Icahn School Of Medicine at Mount Sinai	New York	New York
United States	University of Utah- Huntsman Cancer Institute	Salt Lake City	Utah
United States	Moffitt Cancer Center Research Institute	Tampa	Florida
United States	The University of Arizona Cancer Center	Tucson	Arizona
United States	University of Kansas Cancer Center	Westwood	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Idera Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 2: Number of Participants With Objective Response Rate (ORR) Using RECIST v1.1	The following combined analysis populations were used for outcome measures (efficacy analysis N=53): The Phase 2, 8 mg Tilso/Ipi efficacy evaluable population (N=44); The Phase 1, 8 mg Tilso/Ipi evaluable population (N=9); The ORR for 49 evaluable (4 non-evaluable) participants who received the recommended Phase 2 dose (RP2D) of 8 mg Tilso/Ipi was calculated using the participant's best overall response (BOR).; Per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) for target lesions as assessed by MRI, CT or X-ray: Complete Response (CR) - disappearance of all target lesions; Partial Response (PR) - >=30% decrease from baseline of the sum of diameters of all target lesions; Stable Disease (SD) - does not qualify for CR, PR or Progression; Progressive Disease (PD) - 20% increase in the sum of diameters of target lesions.; Overall Response = CR or PR	33 weeks (29 weeks of treatment, 4 weeks follow up)
Secondary	Phase 2: Progression-free Survival	The following combined analysis populations were used for outcome measures (efficacy analysis N=53): The Phase 2, 8 mg Tilso/Ipi efficacy evaluable population N=40 (44 with 4 non-evaluable); The Phase 1, 8 mg Tilso/Ipi evaluable population (N=9); Progression-free survival was defined as the number of months from the initiation of treatment to confirmed disease progression using RECIST v1.1 or death from any cause.	33 weeks (29 weeks of treatment, 4 weeks follow up)
Secondary	Phase 2: Overall Survival - 6 Months	The following combined analysis populations were used for outcome measures (efficacy analysis N=53): The Phase 2, 8 mg Tilso/Ipi efficacy evaluable population N=44 (40 with 4 non-evaluable); The Phase 1, 8 mg Tilso/Ipi evaluable population (N=9); Overall survival was defined as the number of months from initiation of treatment to death from any cause.	6 months
Secondary	Phase 2: Overall Survival - 12 Months	The following combined analysis populations were used for outcome measures (efficacy analysis N=53): The Phase 2, 8 mg Tilso/Ipi efficacy evaluable population N=40 (44 with 4 non-evaluable); The Phase 1, 8 mg Tilso/Ipi evaluable population (N=9); Overall survival was defined as the number of months from initiation of treatment to death from any cause.	12 months

External Links

•   For more information